Colon Cancer, Rectal Cancer
Conditions
Keywords
locally advanced, metastatic colon, rectal cancer
Brief summary
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects. The purpose of the Phase II portion is to find out how safe the study drug is when taken at the highest dose in a larger group of subjects.
Detailed description
This open-label, multicenter, randomized study will consist of a Phase Ib portion: a safety run-in period with 3 ascending doses of E7820; and a Phase II portion: a randomized 2-arm design. Approximately 95 patients with measurable, nonresectable locally advanced or metastatic colorectal adenocarcinoma, who have failed first-line chemotherapy, will be enrolled in the study (approximately 12 to 15 patients in the Phase Ib portion and 80 patients in the Phase II portion). Patients will only participate in either the Phase Ib or the Phase II portion of the study. Patients will receive up to a planned total of 12 cycles of study treatment unless there is occurrence of progressive disease, unacceptable toxicity, withdrawal of consent, withdrawal by the Investigator, lost to follow-up, or death, whichever occurs first. After 12 cycles, patients who demonstrate clinical benefit may continue single agent E7820 for long as clinical benefit is sustained and the treatment is well tolerated. If the treating physician does not feel comfortable discontinuing chemotherapy after 12 cycles, further chemotherapy may be considered following discussion with the medical monitor and sponsor.
Interventions
DRUGFOLFIRI
Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).
DRUGE7820
Test product: dose and mode of administration: E7820 is administered orally in tablet form once daily, every day of each 14-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Pase II portion, the dose will be the MTD in combination with Irinotecan, as determined during the Phase ib portion of the study. The irinotecan regimen consists of an irinotecan dose of 180 mg/m2 by IV infusion once every 2 weeks (Day 1 of each 14-day cycle).
Sponsors
PharmaBio Development Inc.
Eisai Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients may be entered in the study only if they meet all of the following criteria: 1. Male or female patient greater than or equal to 18 years of age; 2. Histologically or cytologically confirmed nonresectable locally advanced or metastatic colorectal adenocarcinoma; 3. Patients must have failed a first-line chemotherapy regimen for nonresectable locally advanced or mCRC (first-line 5-FU-based therapies, including but not limited to FOLFOX, FOLFOX 4, mFOLFOX6, CapeOX, single-agent capecitabine, infusional 5-FU, or other chemotherapies. Bevacizumab, cetuximab, panitumumab, and EGFR inhibitors are allowed. Prior treatment with irinotecan or FOLFIRI is not allowed for Phase II). For Phase Ib only, up to 3 prior therapies are allowed (including non-irinotecan containing therapies and adjuvant therapy); 4. At least 1 site of measurable disease by the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) criteria; 5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of less than or equal to 2; 6. Patients must have adequate renal function as evidenced by serum creatinine less than 2 mg/dL and creatinine clearance greater than 50 mL/minute per the Cockcroft and Gault formula; 7. Patients must have adequate bone marrow function as evidenced by absolute neutrophil count (ANC) greater than or equal to 1.5 x 109/L, platelets greater than100 x 109/L, hemoglobin greater than or equal to 9.0 g/dL (a hemoglobin less than 9.0 g/dL at Screening is acceptable if it is corrected to greater than or equal to 9 g/dL by growth factor or transfusion prior to the first dose); 8. Patients must have adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the upper limit of the normal range (ULN), and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (in the case of liver metastases, less than or equal to 5 X ULN).If there are bone metastases, liver-specific alkaline phosphatase may be separated from the total and used to assess liver function instead of total alkaline phosphatase; 9. For patients with hypertension, it must be well controlled. If a patient presents with poorly controlled hypertension, defined as a mean systolic blood pressure greater than or equal to140 mm Hg or mean diastolic blood pressure greater than or equal to 90 mm Hg,antihypertensive medication(s) should be initiated or adjusted with a goal to control the blood pressure less than 140/90 mm Hg. Blood pressure must be reassessed on 2 occasions, consecutively, that are separated by a minimum of 24 hours; 10. Male or female patients of child-producing potential must agree to use double barrier contraception, oral contraceptives, or avoidance of pregnancy measures during the study and for 90 days after the last day of treatment; 11. Females of childbearing potential must have a negative serum pregnancy test at Screening; 12. Females may not be breastfeeding; Ability to understand and willingness to sign a written informed consent.
Exclusion criteria
1. Received chemotherapy, targeted therapy, radiotherapy, surgery, immunotherapy, or treatment in another clinical study within the 30 days prior to commencing study treatment or have not recovered from side effects of all treatment-related toxicities to Grade less than or equal to 1, except for peripheral neuropathy (Grade 1 and Grade 2 are permitted) and alopecia; 2. Previously received irinotecan or irinotecan derivatives in Phase II (irinotecan-containing regimens are allowed in Phase Ib); 3. Previously received anti-alpha 2 integrin therapy; 4. History of other malignancies except: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the uterine cervix; or (3) other curatively treated solid tumor with no evidence of disease for greater than or equal to 5 years; 5. Presence of brain metastases, unless the patient has received adequate treatment at least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids for at least 4 weeks prior to randomization; 6. Are currently receiving any other anticancer treatment; 7. Serious non-healing wound, ulcer, or active bone fracture; 8. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for a major surgical procedure during the course of the study; 9. Refractory nausea and vomiting, malabsorption, significant bowel resection, or any other medical condition that would preclude adequate absorption or result in the inability to take oral medication; 10. Significant cardiovascular impairment (history of congestive heart failure New York Heart Association \[NYHA\] Grade greater than 2, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia); 11. Active hemoptysis (defined as bright red blood of 1/2 teaspoon or more) within the 30 days prior to study entry; 12. Current or recent use (within 7 days) of full-dose warfarin (except low-dose warfarin as required to maintain patency of pre-existing, permanent indwelling IV catheters). For patients receiving warfarin, International Normalization Ratio (INR) should be less than 1.5. Patients may have prophylactic use of low molecular weight heparin; however, therapeutic use of heparin or low molecular weight heparin is not acceptable; 13. History of bleeding diathesis or coagulopathy; 14. Any history of cerebral vascular accident, transient ischemic attack, or Grade greater than or equal to 2 peripheral vascular disease, unless they have had no evidence of active disease for at least 6 months prior to randomization; 15. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1, unless affected area has been removed surgically; 16. Patients with organ allografts requiring immunosuppression; 17. Known positive human immunodeficiency virus (HIV), known hepatitis B surface antigen, or active hepatitis C positive; 18. Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, 5-FU, or leucovorin; 19. Hypersensitivity to sulfonamide derivatives; 20. Have any medical condition that would interfere with the conduct of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b: Maximum Tolerated Dose (MTD) of E7820 With Irinotecan as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 | Up to 12 cycles (each cycle length =14 days) | MTD: maximum dose that was determined to be safe and tolerable for Phase 2.If two dose limiting toxicities (DLTs) occurred at any dose level,MTD: preceding dose/intermediate dose.DLT was graded according to CTCAE v4.0. Includes \>= Grade 3(G3) peripheral neuropathy,\>=G3 nausea/vomiting despite optimal anti-emetic treatment, any other non-hematologic toxicity of \>=G3(except alopecia, single abnormal laboratory values Investigator judged unlikely related to study therapy, had no clinical correlate, resolved in 7 days, hypersensitivity reaction to any of compounds),Grade 4 neutropenia lasting over 7 days,febrile neutropenia(defined as fever \>=38.5 degrees Celsius with absolute neutrophil count below 1.0\*10\^9 per liter, G3 thrombocytopenia with nontraumatic bleeding(without therapeutic systemic anticoagulation)requiring platelet transfusion,Grade 4 thrombocytopenia (with/without nontraumatic bleeding),any study drug-related death,other toxicity dose escalation committee believed to be DLT. |
| Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | From the first dose of study drug up to 28 days after last dose (Up to 1 year and 3 months) | TEAE is defined as an adverse event that had an onset date, or a worsening in severity on or after the first dose of study drug up to the end of the study. Number of participants with TEAEs are reported based on safety assessments of laboratory tests, physical examination, examining bowel movements, regular measurement of vital signs, eastern cooperative oncology group-performance status and electrocardiogram parameter values. SAE is any untoward medical occurrence that at any dose: resulted in death; life threatening required inpatient hospitalization; resulted in persistent, significant disability; is congenital anomaly/birth defect or medically important due to other reasons than above mentioned criteria. Number of participants with TEAEs and SAEs were reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase 2: Progression Free Survival (PFS) | From date of randomization up to 1 year and 2 months | PFS is defined as the time from the date of randomization of a participant until the sooner of (1) the date of first documented progression of such participant's disease (PD) based on Investigator assessments according to response evaluation criteria in solid tumor (RECIST) version (v) 1.1. or; (2) the date of such participant's death due to any cause. PD is defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. |
| Phase 2: Overall Survival (OS) | From date of randomization up to 1 year and 2 months | OS is defined as time from the date of randomization of a participant until the date of death of such participant, regardless of the actual cause of the participant's death. |
| Phase 2: Time to Progression (TTP) | From date of randomization up to 1 year and 2 months | TTP is defined as time from the date of randomization of a participant until the date of first documented progression of such participant's disease. PD is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking in reference the smallest summed longest diameters on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression. |
| Phase 2: Percentage of Participants With Overall Response | From date of randomization up to 1 year and 2 months | ORR is defined as percentage of participants in the study whose best overall response is either complete response (CR) or partial response (PR) based on RECIST v1.1. CR is defined as complete disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to less than 10 mm. PR is defined as at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline summed longest diameters. |
Countries
Argentina, Australia, Brazil, Russia, Ukraine, United States
Participant flow
Recruitment details
Participants took part in the study at 42 investigative sites in Argentina, Australia, Brazil, Russian Federation, Ukraine, and the United States from 30 September 2011 to 22 June 2015.
Pre-assignment details
A total of 82 participants were enrolled in this study. This study consisted of two phases: Phase 1b and Phase 2. In Phase 1b, 14 participants were enrolled and received study treatment and in Phase 2, 68 participants were enrolled and received the study treatment. Participants were randomized in a 1:1 ratio and received either E7820 in combination with irinotecan or FOLFIRI.
Participants by arm
| Arm | Count |
|---|---|
| Phase 1b: Cohort 1: E7820 40 mg + Irinotecan Participants received E7820 40 mg tablets, orally, once daily of each 14-day treatment cycle in combination with irinotecan 180 milligram per square meter (mg/m\^2) as an intravenous infusion on Day 1 of each 14-day cycle (once every 2 weeks) for up to 12 cycles. After 12 cycles, at the discretion of the Investigator and in consultation with the Medical Monitor, participants who were experiencing clinical benefit continued their assigned treatment until PD, unacceptable toxicity, withdrawal of consent, withdrawal by the Investigator, lost to follow-up, or death, whichever occurred first. | 3 |
| Phase 1b: Cohort 2: E7820 70 mg + Irinotecan Participants received E7820 70 mg tablets, orally, once daily of each 14-day treatment cycle in combination with irinotecan 180 mg/m\^2 as an intravenous infusion on Day 1 of each 14-day cycle (once every 2 weeks) for up to 12 cycles. After 12 cycles, at the discretion of the Investigator and in consultation with the Medical Monitor, participants who were experiencing clinical benefit continued their assigned treatment until PD, unacceptable toxicity, withdrawal of consent, withdrawal by the Investigator, lost to follow-up, or death, whichever occurred first. | 8 |
| Phase 1b: Cohort 3: E7820 100 mg + Irinotecan Participants received E7820 100 mg tablets, orally, once daily of each 14-day treatment cycle in combination with irinotecan 180 mg/m\^2 as an intravenous infusion on Day 1 of each 14-day cycle (once every 2 weeks) for up to 12 cycles. After 12 cycles, at the discretion of the Investigator and in consultation with the Medical Monitor, participants who were experiencing clinical benefit continued their assigned treatment until PD, unacceptable toxicity, withdrawal of consent, withdrawal by the Investigator, lost to follow-up, or death, whichever occurred first. | 3 |
| Phase 2: E7820 70 mg + Irinotecan Participants received E7820 70 mg (changed to 50 mg as per protocol amendment 06) as Recommended Phase 2 dose (RP2D) tablets, orally, once daily of each 14-day treatment cycle on Day 1 with Irinotecan 180 mg/m\^2 as an intravenous infusion on Day 1 of each 14-day cycle for up to 12 cycles. After 12 cycles, at the discretion of the Investigator and in consultation with the Medical Monitor, participants who were experiencing clinical benefit continued their assigned treatment until PD, unacceptable toxicity, withdrawal of consent, withdrawal by the Investigator, lost to follow-up, or death, whichever occurred first. | 34 |
| Phase 2: Folfiri Participants received the FOLFIRI regimen, which consisted of irinotecan at 180 mg/m\^2 as an intravenous infusion and leucovorin at 200 mg/m\^2 by intravenous infusion on Day 1 of each cycle, and 5-FU at 400 mg/m\^2 as an intravenous bolus injection followed by a total of 2400 mg/m\^2 by continuous IV infusion over 46 hours over Days 1 and 2 via infusion for up to 12 cycles. After 12 cycles, at the discretion of the Investigator and in consultation with the Medical Monitor, participants who were experiencing clinical benefit continued their assigned treatment until PD, unacceptable toxicity, withdrawal of consent, withdrawal by the Investigator, lost to follow-up, or death, whichever occurred first. | 34 |
| Total | 82 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 0 | 1 | 1 |
| Overall Study | Death | 1 | 5 | 2 | 7 | 7 |
| Overall Study | Lost to Follow-up | 1 | 1 | 0 | 1 | 1 |
| Overall Study | Other | 1 | 0 | 0 | 0 | 1 |
| Overall Study | Physician Decision | 0 | 0 | 0 | 0 | 1 |
| Overall Study | Study termination by Sponsor due to E7820 plus irinotecan being potentially inferior to FOLFIRI | 0 | 2 | 1 | 22 | 20 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 0 | 3 | 3 |
Baseline characteristics
| Characteristic | Phase 1b: Cohort 1: E7820 40 mg + Irinotecan | Phase 1b: Cohort 2: E7820 70 mg + Irinotecan | Phase 1b: Cohort 3: E7820 100 mg + Irinotecan | Phase 2: E7820 70 mg + Irinotecan | Phase 2: Folfiri | Total |
|---|---|---|---|---|---|---|
| Age, Customized <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized >=85 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized Between 18 and 85 years | 3 Participants | 8 Participants | 3 Participants | 34 Participants | 34 Participants | 82 Participants |
| Sex: Female, Male Female | 1 Participants | 3 Participants | 1 Participants | 19 Participants | 16 Participants | 40 Participants |
| Sex: Female, Male Male | 2 Participants | 5 Participants | 2 Participants | 15 Participants | 18 Participants | 42 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 3 | 5 / 8 | 2 / 3 | 7 / 34 | 7 / 34 |
| other Total, other adverse events | 3 / 3 | 8 / 8 | 3 / 3 | 33 / 34 | 33 / 34 |
| serious Total, serious adverse events | 2 / 3 | 1 / 8 | 0 / 3 | 10 / 34 | 8 / 34 |
Outcome results
Primary
Phase 1b: Maximum Tolerated Dose (MTD) of E7820 With Irinotecan as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0
MTD: maximum dose that was determined to be safe and tolerable for Phase 2.If two dose limiting toxicities (DLTs) occurred at any dose level,MTD: preceding dose/intermediate dose.DLT was graded according to CTCAE v4.0. Includes \>= Grade 3(G3) peripheral neuropathy,\>=G3 nausea/vomiting despite optimal anti-emetic treatment, any other non-hematologic toxicity of \>=G3(except alopecia, single abnormal laboratory values Investigator judged unlikely related to study therapy, had no clinical correlate, resolved in 7 days, hypersensitivity reaction to any of compounds),Grade 4 neutropenia lasting over 7 days,febrile neutropenia(defined as fever \>=38.5 degrees Celsius with absolute neutrophil count below 1.0\*10\^9 per liter, G3 thrombocytopenia with nontraumatic bleeding(without therapeutic systemic anticoagulation)requiring platelet transfusion,Grade 4 thrombocytopenia (with/without nontraumatic bleeding),any study drug-related death,other toxicity dose escalation committee believed to be DLT.
Time frame: Up to 12 cycles (each cycle length =14 days)
Population: The safety population included all the participants enrolled in the Phase 1b portion of this study, except for those who (i) dropped out of the study prior to receiving any study drug, or (ii) were without any safety assessment following the first dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1b, All Participants | Phase 1b: Maximum Tolerated Dose (MTD) of E7820 With Irinotecan as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 | NA milligram (mg) |
Primary
Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
TEAE is defined as an adverse event that had an onset date, or a worsening in severity on or after the first dose of study drug up to the end of the study. Number of participants with TEAEs are reported based on safety assessments of laboratory tests, physical examination, examining bowel movements, regular measurement of vital signs, eastern cooperative oncology group-performance status and electrocardiogram parameter values. SAE is any untoward medical occurrence that at any dose: resulted in death; life threatening required inpatient hospitalization; resulted in persistent, significant disability; is congenital anomaly/birth defect or medically important due to other reasons than above mentioned criteria. Number of participants with TEAEs and SAEs were reported.
Time frame: From the first dose of study drug up to 28 days after last dose (Up to 1 year and 3 months)
Population: The safety population included all participants enrolled and randomized to treatment in the Phase 2 portion of this study, except for those who (i) dropped out prior to receiving any study drug, or (ii) were without any safety assessment following the first dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b, All Participants | Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAEs | 34 Participants |
| Phase 1b, All Participants | Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 10 Participants |
| Phase 2: Folfiri | Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAEs | 34 Participants |
| Phase 2: Folfiri | Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 8 Participants |
Secondary
Phase 2: Overall Survival (OS)
OS is defined as time from the date of randomization of a participant until the date of death of such participant, regardless of the actual cause of the participant's death.
Time frame: From date of randomization up to 1 year and 2 months
Population: MITT analysis set included all participants who were randomized and received at least one dose of study medication without major protocol eligibility violations.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1b, All Participants | Phase 2: Overall Survival (OS) | NA weeks |
| Phase 2: Folfiri | Phase 2: Overall Survival (OS) | NA weeks |
Secondary
Phase 2: Percentage of Participants With Overall Response
ORR is defined as percentage of participants in the study whose best overall response is either complete response (CR) or partial response (PR) based on RECIST v1.1. CR is defined as complete disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to less than 10 mm. PR is defined as at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline summed longest diameters.
Time frame: From date of randomization up to 1 year and 2 months
Population: MITT analysis set included all participants who were randomized and received at least one dose of study medication without major protocol eligibility violations.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1b, All Participants | Phase 2: Percentage of Participants With Overall Response | 20.6 percentage of participants |
| Phase 2: Folfiri | Phase 2: Percentage of Participants With Overall Response | 20.6 percentage of participants |
Secondary
Phase 2: Progression Free Survival (PFS)
PFS is defined as the time from the date of randomization of a participant until the sooner of (1) the date of first documented progression of such participant's disease (PD) based on Investigator assessments according to response evaluation criteria in solid tumor (RECIST) version (v) 1.1. or; (2) the date of such participant's death due to any cause. PD is defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions.
Time frame: From date of randomization up to 1 year and 2 months
Population: Modified intent-to-treat (MITT) analysis set included all participants who were randomized and received at least one dose of study medication without major protocol eligibility violations.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1b, All Participants | Phase 2: Progression Free Survival (PFS) | 17.1 weeks |
| Phase 2: Folfiri | Phase 2: Progression Free Survival (PFS) | 33.7 weeks |
Secondary
Phase 2: Time to Progression (TTP)
TTP is defined as time from the date of randomization of a participant until the date of first documented progression of such participant's disease. PD is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking in reference the smallest summed longest diameters on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of 1 or more new lesions was also considered progression.
Time frame: From date of randomization up to 1 year and 2 months
Population: MITT analysis set included all participants who were randomized and received at least one dose of study medication without major protocol eligibility violations.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1b, All Participants | Phase 2: Time to Progression (TTP) | 23.7 weeks |
| Phase 2: Folfiri | Phase 2: Time to Progression (TTP) | 33.7 weeks |